TUGAS ANALISIS JURNAL

KEPERAWATAN MEDIKAL BEDAH

EVIDENCE BASED AND NURSE

DOSEN PENGAMPU
NS. Arif Hidayatullah, S.Kep., M.Kep. Sp. Kep. MB
DI SUSUN OLEH :
ANA YULITA NOVITRI 08200100188

SEKOLAH TINGGI ILMU KESEHATAN INDONESIA MAJU

T.A 2020/2021
Judul jurnal : cerebrovascular events among elderly nursing home patients treated with
conventional or atypical antipsychotics

Tahun terbit : 10 februari 2005

Tim peneliti : Rosa Liperoti, M.D., M.P.H.; Giovanni Gambassi, M.D.; Kate L. Lapane,
Ph.D.; Claire Chiang, M.S.; Claudio Pedone, M.D., Ph.D., M.P.H.; Vincent Mor, Ph.D.; and
Roberto Bernabei, M.D.

Metode penelitian :

- Lokasi penelitian : panti jompo di 6 negara bagian amerika serikat dengan

menggunakan penilaian sistematis geriatri
- Sample penelitian : usia lanjut

Tujuan penelitian : Ada kekhawatiran tentang kemungkinan exists peningkatan risiko

kejadian serebrovaskular (CVE) di antara pasien usia lanjut yang menerima risperidone atau
olanzapin. Kami memperkirakan efek atipikal dan antipsikotik konvensional pada risiko CVE
di antara pasien panti jompo lansia dengan demensia

Hasil penelitian : dari hasil penelitian menunjukan bahwa tidak ada pengaruh terhadap
kejadian cerebrovaskular pada usia lanjut penderita alzheimer/demensia yang mendapat
terapi Antipsikotik Konvensional atau Atipikal.

Refrensi :

. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of

schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371–1376
2. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of
antipsychotics in the elderly. J Clin Psychiatry 1999;60(suppl 8):29–41 3. Kapur S,
Remington G. Atypical antipsychotics [editorial]. BMJ 2000;321:1360–1361 4. Glick ID,
Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and
new populations. J Psychiatr Res 2001;35:187–191 5. Liperoti R, Mor V, Lapane KL, et al.
The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003;64:1106–1112 6.
American Geriatrics Society and American Association for Geriatric Psychiatry. Consensus
statement on improving the quality of mental health care in US nursing homes: management
of depression and behavioral symptoms associated with dementia. J Am Geriatr Soc
2003;51:1287–1298 7. Nasrallah H. A review of the effect of atypical antipsychotics on
weight. Psychoneuroendocrinology 2003;28(suppl 1):83–96 8. Dwyer DS, Bradley RJ,
Kablinger AS, et al. Glucose metabolism in relation to schizophrenia and antipsychotic drug
treatment. Ann Clin Psychiatry 2001;13:103–113 9. Liperoti R, Gambassi G, Lapane KL, et
al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular
arrhythmias or cardiac arrest. Arch Intern Med 2005;165:696–701 10. Straus SM, Bleumink
GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med
2004;164:1293–1297 11. Hägg S, Spigset O. Antipsychotic-induced venous
thromboembolism. CNS Drugs 2002;16:765–776 12. Wooltorton E. Risperidone (Risperdal):
increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269–1270 13.
Wooltorton E. Olanzapine (Zyprexa): increased rate of cerebrovascular events in dementia
trials. CMAJ 2004;170:1395 14. Brodaty H, Ames D, Snowdon J, et al. A randomized
placebo-controlled trial of risperidone for the treatment of aggression, agitation, and
psychosis of dementia. J Clin Psychiatry 2003;64:134–143 15. De Deyn PP, Rabheru K,
Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for
behavioral symptoms of dementia. Neurology 1999;53:946–955 16. Katz IR, Jeste DV,
Mintzer JE, et al, for the Risperidone Study Group. Comparison of risperidone and placebo
for psychosis and behavioral disturbances associated with demen tia: a randomized, double-
blind trial. J Clin Psychiatry 1999;60:107–115 17. Street JS, Clark WS, Gannon KS, et al.
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer
disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The
HGEU Study Group. Arch Gen Psychiatry 2000;57:968–976 18. De Deyn PP, Carrasco MM,
Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without
associated behavioral disturbances in patients with Alzheimer’s disease. Int J Geriatr
Psychiatry 2004;19:115–126 19. Bernabei R, Gambassi G, Lapane KL, et al. Characteristics
of the SAGE database: a new resource for research on outcomes in long-term care. SAGE
(Systematic Assessment of Geriatric drug use via Epidemiology) Study Group. J Gerontol A
Biol Sci Med Sci 1999:54:M25–M33 20. Gambassi G, Landi F, Peng L, et al. Validity of
diagnostic and drug data in standardized nursing home assessments: potential for geriatric
pharmacoepidemiology. Med Care 1998;36:167–179.